Mankind, BDR Pharma join hands to launch anti Covid-19 pill Molulife
Mankind Pharma on Wednesday said it has joined hands with BDR Pharmaceuticals to launch oral anti COVID-19 pill Molulife (Molnupiravir) in the country. The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma, the company said in a statement.
On Tuesday, the Drugs Controller General of India (DCGI) granted permission for restricted use of antiviral medication Molnupiravir under emergency situation for treatment of COVID-19 in adult patients who have a high risk of progression of the disease.
This launch further enhances the COVID-19 treatment portfolio in BDR’s product basket with the addition of generic Molnupiravir. We are pleased to collaborate with Mankind Pharma to take one step forward in fighting the virus,” BDR Pharma Director Business Development Raheel Shah stated. Mankind Pharma Senior President (Sales & Marketing) Sanjay Koul noted that a pill for COVID-19 is bound to go miles in strengthening defense against COVID-19 battle.
Covid antiviral pill launched at Rs 1,399 for full 5-day course
MUMBAI Molnupiravir, the antiviral drug which recently got emergency use approval for treatment of mild to moderate Covid-19 in India was launched on Monday at Rs 1,399 for the full five-day course, making it one of the cheapest antiviral coronavirus therapies during the pandemic.
Over a dozen companies, including Hetero, Sun Pharma, Natco and Dr Reddy’s are in the process of rolling out the oral therapy developed by Merck and and its partner, Ridgeback Biotherapeutics, at prices ranging between Rs 1,500 and Rs 2.500 for the complete treatment, sources told TOI. The antiviral pill is being considered a potential gamechanger globally in Covid treatment as remdesivit used till now is administered intravenously, and in hospital settings.
Mankind Pharma, which has tied up with BDR Pharmaceuticals. introduced its antiviral Molulife (200 mg) in Delhi and certain other parts o on Monday, a company official said. Further, Sun Pharma has priced the antiviral at around Rs 1.500 for the full course, and is making its Mobever available in markets where there are more cases, and gradually across India. the country
The recommended dose of molnupiravir is 800 mg twice a day for five days Given the stiff competition among the market players, the treatment cost will remain competitive and affordable for patients, experts said. Molnupiravir, is also the first oral anti-Covid pill approved by UK’S drug regulator, who recently the US Food and Drug Administration cleared it for the treatment of mild-to-moderate Covid-19 in adults, and for those who are at a high risk for progression to severe disease, including hospitalization or death.
Post the USFDA nod. Drugs Controller General of India granted permission for restricted use of moinupiravir for treatment of adult patients with SpO2 93%, and who have high risk of progression of the disease.
Earlier in June, MSD signed licensing agreements with five generic companies including Sun Pharma, Cipla, Torrent, Emcure and Dr Reddy’s to manufacture and supply molnupiravir in India, and to over 100 low and middle-income countries.
At Mankind Pharma, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs, Mankind Pharma came into existence in 1986, and in 1991, the company was formed into a legal corporation. However, it actively started working as a fully-integrated pharmaceutical company in 1995. Today, Mankind has an employee base of over 14,000 and is racing towards $1 Billion.
We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Adiction, Gas-O-Fast, Kaloree 1 and many others.